INTRODUCTION
============

Surgical site infection (SSI) is a critical aspect in the surgical field. SSI occurs in 1.9% of surgeries, and varies among populations, surgical procedures, and instrumentation \[[@b3-jkns-2019-0161],[@b10-jkns-2019-0161],[@b12-jkns-2019-0161],[@b13-jkns-2019-0161],[@b15-jkns-2019-0161],[@b24-jkns-2019-0161]\]. SSI results in a significant morbidity and financial burden due to longer hospital stay, readmission, and repeated procedures \[[@b3-jkns-2019-0161],[@b5-jkns-2019-0161],[@b18-jkns-2019-0161],[@b34-jkns-2019-0161]\]. Even though most surgeons do their best to prevent it, SSI is still a challenging issue. SSI is emphasized especially when the surgical procedures include instrumentation or graft application \[[@b24-jkns-2019-0161],[@b29-jkns-2019-0161]\]. In an attempt to decline infection rate, local application of antibiotics is performed to maintain sufficiently high drug concentrations for durable periods in the surgical wound space. A variety of methods for local release have been used to deliver antibiotics, including direct application of vancomycin powder, polymethylmethacrylate (PMMA), bone grafts, and natural polymers. As one of the natural polymers, fibrin sealant is a familiar term in the neurosurgical field because many surgeons use it for hemostasis, preventing cerebrospinal fluid (CSF) leakage, controlling sinus bleeding in cranial surgery, or sealing dead space in spinal surgery. Fibrin sealant consists of fibrin, thrombin, factor XIII, and Ca++. Since it is naturally present in the human body, it has several advantages over other sealants due to low inflammatory response, lack of immune interference, and natural absorption. Recent studies indicate that fibrin sealant acts as a biodegradable drug delivery agent as well as in hemostasis \[[@b2-jkns-2019-0161],[@b25-jkns-2019-0161],[@b28-jkns-2019-0161],[@b31-jkns-2019-0161]\]. Morishima et al. \[[@b23-jkns-2019-0161]\] and Ozaki et al. \[[@b25-jkns-2019-0161]\] reported that vancomycin-impregnated fibrin sealant effectively prevented prosthetic graft infection. Tofuku et al. \[[@b31-jkns-2019-0161]\] reported that the zone of inhibition for antibiotic-impregnated fibrin sealant is maintained for at least 4 weeks. However, the ideal antibiotic release from antibiotic-impregnated polymers still needs to be investigated. Further, clinical evidence regarding drug delivery characteristics of fibrin sealant is still lacking. This study will support the use of fibrin sealant as a drug delivery agent. The outcome of this study will determine the optimal dosage in clinical use and the relationship between time and the antibiotic concentration in the fibrin sealant for the management of SSI.

MATERIALS AND METHODS
=====================

This study was approved by the Institutional Review Board of Inje University Ilsan Paik hospital (NON2018-005), which waived the need to obtain patient consent because this is *in vitro* study about antibiotic release from fibrin sealant. This study was designed to investigate bacterial susceptibility and the sustainability of vancomycin-impregnated fibrin sealant for two consecutive weeks. The fibrin sealant used in this study was obtained from Beriplast^®^ kit (CSL Behring GmbH, Marburg, Germany). A disc diffusion test was performed using Blood Agar Plates (BAPs) and methicillin-resistant *Staphylococcus aureus* (MRSA) (ATCC29213) for the measurement of bacterial inhibition. Elution test was performed for measuring continuous drug release using high-performance liquid chromatography (Agilent 1200 Infinity LC, Agilent technologies, Santa Clara, CA, USA).

Disc diffusion test
-------------------

Each set of vancomycin-impregnated fibrin sealants was prepared. Materials were subjected to agar diffusion testing to determine whether the sealant pieces possessed antimicrobial activity. The test materials also included drug-free mixtures without vancomycin as controls. These test materials were placed on agar plates and inoculated with a clinical biofilmforming strain of MRSA. The materials were incubated aerobically in an incubation chamber at 37℃. Further, to determine the duration of antimicrobial activity, entire mixtures of vancomycin-impregnated fibrin sealant were incubated for 1 day. During the incubation period, the antibiotic diffused into the bacteria-seeded agar. The zone of bacterial growth inhibition was evident as a clear region surrounding the test material using MRSA strains in this study ([Fig. 1](#f1-jkns-2019-0161){ref-type="fig"}). The minimum inhibitory concentration (MIC) was defined as the lowest concentration of vancomycin that inhibited visible growth of the test bacteria.

### Organism preparation

MRSA were used in this study. MRSA were preserved in skimmed-milk broth stored at below -65°C until use. The culture was incubated in sterile BAPs at 37°C for 24 hours to obtain isolated colonies.

### Determination of the MIC of MRSA

Using the VITEK AST-P601 (bioMérieux, Marcy l'Etoile, France) card and the VITEK Vitek-two, the MIC of vancomycin on MRSA was measured using the standard protocol. In these species, the MIC was 1.0 µg/mL. In the susceptibility test for vancomycin, a clear zone diameter greater than 15 mm was determined as acceptable.

### Zone of inhibition test for antibacterial activity

#### Preparation of biodegradable drug delivery materials

Fibrin sealant was removed from the refrigerator and allowed to thaw for at least 30 minutes before application for a better mixture. Two concentrations of vancomycin (Hanomycin, Samjin pharmaceuticals, Seoul, Korea) were used in this study : 500 mg of vancomycin was dissolved in 1 mL and in 2 mL of sterile saline solution for concentrations (a) 500 mg/mL and (b) 250 mg/mL respectively. For each concentration, 1 mL of the vancomycin solution was added to the thrombin solution (2 mL) of fibrin sealant kit and shaken to incorporate. The mixture was then prepared as per fibrin sealant kit recommendations with the fibrinogen solution (3 mL). The sealant (Thrombin-vancomycin mixture+fibrinogen) formed 6 mL in total that was then applied to cell culture wells to form uniformsized (0.1 mL, 6.4 mm diameter) discs. Each disc contained approximately 8.33 mg (defined as concentration 1 \[C1\], n=9) and 4.167 mg (C2, n=9) of vancomycin for (a) and (b) respectively.

#### Five different consecutive dose diluted antibiotic-loaded fibrin sealant discs

In addition to the two different antibiotic-diluted discs, further consecutive diluted antibiotic-loaded fibrin sealant discs were used to compare the zone of inhibition among different concentrations of antibiotic-loaded discs. Standard procedure for the preparation of MRSA cell culture and inoculation onto BAP was performed as described previously for the zone of inhibition method. In total, 500 mg of vancomycin was dissolved in 1 ml of sterile saline solution. This was diluted by 10- fold (C3, n=3), 100-fold (C4, n=3), and 1000-fold (C5, n=3) to incorporate into fibrin sealant. The antibiotic-loaded fibrin sealant was then molded into 0.1 mL (6.7--7.0 mm in diameter) discs with concentrations of 0.83 mg/disc, 0.083 mg/disc, and 0.0083 mg/disc, for C3, C4, and C5 respectively. The discs were placed in the middle of MRSA inoculated BAPs in triplicate and were incubated at 37℃ for 24 hours.

#### Preparation of plates

MRSA (ATCC25923) culture was diluted to a cell density of 0.5 to 0.6 Macf using Au sterile saline (NaCl) solution as measured with VITEK Denscichek. The final bacterial suspension was inoculated onto sterile BAPs incubated at 37°C overnight. Antibiotic-loaded sealant discs (100 µL) were placed at the center of the agar plates in triplicate. A set of triplicates with no treatment (no sealant, no vancomycin loaded sealant) was used as the control. The zone of inhibition, which diameter of clear circular zone, was measured at 24 hours after incubation time. During the experimental period, all plates were incubated at 37°C. The area of the zone of inhibition was then calculated as described by Cashman et al. \[[@b8-jkns-2019-0161]\].

Elution assays
--------------

The *in vitro* drug release profile was studied with two different sets of drug concentrations (8.33 mg/disc and 4.167 mg/disc, C1 and C2, respectively) and the data were subjected to kinetic interpretation. The drug release profiles of loaded and unloaded fibrin sealant were measured at different time schedules during 24 hours, 48 hours, 3 days, 5 days, 7 days, and 2 weeks. This quantitative test measured the sustained release and change in concentration over time using HPLC.

### Measurement of Cumulative vancomycin release during 2 consecutive weeks

Antibiotic impregnated fibrin sealant discs with two different concentrations of vancomycin were used; the C1 and C2 discs contained approximately 8.33 mg/disc (0.1 mL) and 4.167 mg/disc of vancomycin, respectively. Discs were produced using the same method as in the disk diffusion test. To determine the release characteristics of vancomycin from the two different vancomycin concentrations loaded sealant discs (C1 and C2), each of the pre-prepared sealant discs (1 disc per tube) was placed in 10-mL tubes containing 10 mL of phosphate buffer solution (PBS), in triplicate. The dissolution set was incubated at 37°C and at 0 minute, 10 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 48 hours, 7 days, and 14 days, 500-µL aliquots were collected. Vancomycin concentrations in the samples were measured using HPLC. The dissolution sets were then incubated at 37°C.

The paired triple sets of tube with each C1 and C2 loaded fibrin sealant disc in 10 mL of PBS were used in order to measure the rate of continuous vancomycin release. Each of 1.25 mL PBS samples were taken from each set of tube at 10 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, 48 hours, 7 days, and 14 days ([Fig. 2](#f2-jkns-2019-0161){ref-type="fig"}). After each sampling, 1.25 mL of PBS was replaced. To avoid a calculation error due to replacement, we corrected the PBS volume when we measured the released vancomycin. The equation of calibration curve for HPLC analysis was y=15.797x + 90.264 (R^2^=1.000) ([Fig. 3](#f3-jkns-2019-0161){ref-type="fig"}).

### Elution assay for Conditional release of vancomycin with two different PBS turnovers (daily total versus daily half exchange of PBS)

Although being an *in vitro* study, we simulated in-vivo conditions by assuming body fluid exchange which might be caused by drain out, pooled hematoma, or serous fluid. Two types of conditional elution test were performed with a PBS exchanges in two different ways ([Fig. 2](#f2-jkns-2019-0161){ref-type="fig"}). A : measurement of conditional vancomycin release with daily total PBS exchange test : to assess the release rate with total fluid turnover, the solution was replaced with 10 mL of fresh PBS at 24 hours intervals for 5 consecutive days. B : measurement of conditional vancomycin release with daily half PBS exchange : to assess the release rate with half fluid turnover, 5 mL of the solution was replaced with 5 mL of fresh PBS at 24 hours intervals for 5 consecutive days. The 1.25 mL sample was taken at the time stated above and stored at -60°C for a maximum of three days before being assessed for HPLC analysis.

Statistical analysis
--------------------

The results are measured as mean and standard deviation. Both paired and unpaired t-test and one-way analysis of variance (ANOVA) were used as the analysis method. In all cases, a significance level of *p*\<0.05 denoted statistical significance. All statistical analyses were performed using GraphPad Prism 8 (GraphPad Software, Inc., San Diego, CA, USA).

RESULTS
=======

Antibacterial measurement of zone of inhibition in disk-diffusion test
----------------------------------------------------------------------

The summary of measurement of zone inhibition in each sets of blood agar plate was shown in [Table 1](#t1-jkns-2019-0161){ref-type="table"}. The average diameter of clear zone for antibacterial growth inhibition was 2.54±0.07 cm and 2.61±0.12 cm in BAP diffusion test with two fibrin sealant discs which loaded with higher dose of vancomycin concentrations (8.33 mg/disc of C1 and 4.167 mg/disc of C2, respectively). For C3, C4, and C5, the zone of inhibition was correlated to the dilutions with gradual decline of mean diameter of 2.13±0.15 cm, 1.67±0.06 cm, and 1.23±0.15 cm, respectively ([Table 1](#t1-jkns-2019-0161){ref-type="table"}).

Under the 4.167 mg/disc, the vancomycin concentration and zone of inhibition seemed to follow a dose-dependent relationship (*p*\<0.05, ANOVA). Furthermore, post-hoc analysis by Tukey's HSD showed a statistically significant different among the five groups except for C1--C2, and C4--C5 ([Fig. 4](#f4-jkns-2019-0161){ref-type="fig"}). All concentrations except for C5 (0.0083 mg/disc) fulfilled the threshold of the antibiotic susceptibility test at a clear zone diameter of 15 mm.

Elution test for cumulative and conditional vancomycin-release measurement using HPLC
-------------------------------------------------------------------------------------

Irrespective of release behavior, all results showed a sustained release of vancomycin from the vancomycin-loaded sealant. After 2 weeks of observation, the vancomycin impregnated fibrin sealant discs had still not degraded.

### Measurement of cumulative antibiotic release (day 0 to 2 weeks)

The results of the cumulative measurement of vancomycin release lasting for 2 weeks are as follows. After inoculation of fibrin sealant discs containing two different concentrations of vancomycin (C1 and C2) into each set of PBS tubes, vancomycin release in PBS lasted for 10 minutes and was measured more than 50 µg/mL in both sets of PBS. This cumulative concentration was comparably high over therapeutic drug monitoring (TDM) which therapeutic efficacy dose recommended 10--20 µg/mL in blood. The cumulative antibiotic release was continuously increased for 48 hours and reached maximum concentration at 48 hours. The average maximum concentration reached at 400 µg/mL and 340 µg/mL of C1 and C2 elution test, respectively. Then, the cumulative concentration was maintained constant for 2 consecutive weeks ([Fig. 5](#f5-jkns-2019-0161){ref-type="fig"}).

### Measurement of conditional vancomycin release with daily total PBS exchange (day 1 to day 5)

The result of the conditional vancomycin release with daily total PBS exchange for 5 days were as follows. The fibrin sealant discs containing two different concentrations of vancomycin (C1 and C2) were inoculated into each set of PBS tubes. The vancomycin release in PBS on day 1 reached more than 200 µg/mL of vancomycin in PBS tube of C1 whereas the other tube set of C2 released more than 100 µg/mL. After total PBS exchange in each set of PBS tubes, the vancomycin release concentration on day 2 was decreased by almost half compared to the previous day. The mean concentrations of the antibiotic release in C1 and C2 were decreased to 26.12 µg/mL and 24.06 µg/mL, respectively, on the third and fourth days following continuous daily exchange. Until three consecutive total exchange of PBS, however, the vancomycin concentration in PBS was maintained more than that of TDM (10--20 µg/mL). On the last day 5, the average concentration of vancomycin was dropped to less than 10 µg/mL ([Fig. 6](#f6-jkns-2019-0161){ref-type="fig"}) following daily total PBS exchange.

### Measurement of conditional vancomycin release with daily half PBS exchange (day 1 to day 5)

The measurement results from daily half PBS exchange were as follows. On day 1 after inoculation of both C1 and C2 impregnated fibrin sealant discs in each set of PBS tubes, the vancomycin release was measured consistently about 200 µg/mL of vancomycin. Similarly, the vancomycin release rate decreased to half on day 2 following the half exchange of PBS, but the conditional release rate remained at a concentration similar to day 2 until day 3. As following consecutive daily half exchange, the vancomycin concentration was gradually decreased to 20.34 µg/mL and 17.58 µg/mL on day 4 and day 5, respectively and remained at a concentration higher than TDM in blood ([Fig. 7](#f7-jkns-2019-0161){ref-type="fig"}).

Summary of results
------------------

In summary, C1 (8.33 mg/disc) and C2 (4.167 mg/disc) did not show a difference in both the disk-diffusion test and elution assay. This suggests that the optimal vancomycin concentration for clinical application is likely at least more than 4.167 mg/disc for therapeutic purpose. According to the elution assay, released vancomycin concentration was higher than TDM even in 10 minutes after application. Further, the peak amount of released vancomycin was achieved in 24--48 hours. Additionally, in both daily total and half exchange of PBS, the vancomycin concentration was over the therapeutic concentration for 4 days and 5 days, respectively. Cumulative release of vancomycin will last more than 2 weeks and will maintain a sufficient therapeutic antibiotic level over MIC.

DISCUSSION
==========

Microvascular networks in uncomplicated surgical wound enhanced to reach sufficient intravenous antibiotic level by angiogenesis in healing process. However, complicated wounds such as surgical dead space filled with body fluid collection prohibit to maintain intravenous antibiotic concentration. In this compromised surgical wound, intravenous administration of antibiotics during postoperative periods often limits the local drug concentrations above MIC and is also influenced by systemic toxicity in general (e.g., diarrhea, rash, or phlebitis, etc.), renal toxicity, and leukopenia in long term use due to lack of antibiotics penetration into the surgical wound \[[@b7-jkns-2019-0161]\].

Local antibiotics application has been studied as an alternative to solve this problem. On the other hand, local application of antibiotics could maintain the drug concentration for a longer period with less systemic toxicity \[[@b1-jkns-2019-0161]\]. According to their specific method of use, topical antibiotic application can be divided into three group; 1) direct powder application like vancomycin, 2) use of non-absorbable products such as PMMA, and 3) biodegradable agents including autologous bone grafts, synthetic polymers, and natural polymers like fibrin sealant. In the neurosurgical field, for both cranial and spinal surgery, many clinicians are facing the prevention and treatment of postoperative surgical wound infection related with CSF leakage via dura suture, sinus air cells that often resulted from the reconstruction of trans-sphenoidal surgery, skull base surgery, brain and spine trauma, and implantation of device (e.g., shunt operation or spinal surgery). A biofilm is defined as a community of micro-organisms attached to a surface, and embedded within a matrix of extracellular polymeric substances. As instrumentation is a good source of biofilm formation, it is important that antibiotic concentrations be maintained above the MIC for several days after surgery, especially if the procedure involves instrumentation or vascular or artificial grafts \[[@b6-jkns-2019-0161],[@b26-jkns-2019-0161]\]. Traditionally, antibiotic impregnated PMMA has been widely used in complicated orthopedic surgery such hip and long bone surgical infection. This drug delivery carrier has been proved to use as a vehicle of locally sustainable drug release in surgical dead space. However, this non-biodegradable device has a disadvantage to be removed after the use despite of its advantage of stable local drug release \[[@b17-jkns-2019-0161]\]. Topical vancomycin powder application is simple and the easiest way to provide but has serious limitation of sustainable release due to lack of delivery carrier. Followings are summaries in cons and pros of the ways for topical antibiotic application and its use of delivery vehicles.

First, direct antibiotic powder application is one of the easiest methods to reduce postoperative infection in both cranial and spinal surgery \[[@b3-jkns-2019-0161],[@b11-jkns-2019-0161],[@b12-jkns-2019-0161],[@b26-jkns-2019-0161],[@b29-jkns-2019-0161],[@b30-jkns-2019-0161]\]. Direct powder application is valuable for cost saving by reducing repeat admission and extra surgeries \[[@b11-jkns-2019-0161]\]. It can enhance the local concentration of vancomycin while blood vancomycin levels are still undetectable. Adverse effects of vancomycin are rarely reported. Khan et al. \[[@b18-jkns-2019-0161]\] reported that applying vancomycin powder in surgical field provides absolute risk reduction and a relative risk reduction of 2.8% and 68%, respectively. In other words, the chance of SSI is 2.99 times higher in the control group \[[@b18-jkns-2019-0161]\]. The limitation of vancomycin powder is a lack of sustainable carrying vehicle which means that the drug concentration cannot be maintained in case of rapid fluid exchange conditions on the operation bed (e.g., significant postoperative bleeding, negative pressure drainage of barovac, or body fluid exchange).

In terms of providing an effective use of local drug release, therefore, PMMA has been widely used as drug delivery materials, especially in orthopedic and vascular graft surgeries since 1970s. It can effectively fill the surgical dead space as well as release antibiotics; it can also be made in a variety of sizes or shapes so that surgeons can apply them according to different situations. Many studies have described antibiotic release from PMMA. An *in vitro* study by Charlton-Ouw et al. \[[@b9-jkns-2019-0161]\] reported the efficacy of PMMA when combined with various antibiotics that were frequently used in abdominal graft surgery. However, it could also be a source of infection or form a granulation tissue, provided it remains in the soft tissue; re-operation is essential to remove the beads \[[@b4-jkns-2019-0161],[@b14-jkns-2019-0161],[@b21-jkns-2019-0161]\].

Finally, in an attempt to solve the problems posed by PMMA and vancomycin powder application, surgeons have investigated biodegradable materials. In addition to bone graft and substances such as calcium sulfate, hydroxyapatite, demineralized bone matrix, as a biodegradable carriers synthetic and natural polymers are used including synthetic hydrogel, poly-lactic acid, poly-lactic-co-glycolic acid, and collagen sponge and fibrin sealant, etc. Fibrin sealant, one of the biodegradable polymers, has been employed in surgical drug delivery systems. The FDA approved its commercial use as a hemostat in 1998 \[[@b22-jkns-2019-0161]\]. It has since been used as a topical hemostat for sealing the dura mater incision line, or filling dead space in spinal surgery \[[@b2-jkns-2019-0161],[@b16-jkns-2019-0161],[@b23-jkns-2019-0161],[@b25-jkns-2019-0161],[@b28-jkns-2019-0161]\]. In case of venous sinus injury during craniotomy, many neurosurgeons use this item to achieve bleeding control as well as to physically defend the sinuses \[[@b27-jkns-2019-0161],[@b32-jkns-2019-0161]\]. Furthermore, when the frontal sinus is opened, antibiotic-impregnated fibrin glue replaces gentamycin soaked gel foams, thus packing the sinus \[[@b33-jkns-2019-0161]\]. There have been several reports about the clinical use of fibrin sealant as a drug delivery agent; however, previous studies have usually focused on the zone of inhibition test to show the effectiveness of fibrin glue with antibiotics \[[@b8-jkns-2019-0161]\].

In this study, we propose the optimal therapeutic range of vancomycin concentration that impregnates fibrin sealant carriers to maintain over MIC or therapeutic dose and provides effective antibacterial effects in disk diffusion test and elution test. In general usage, practical concentration of C1 (8.36 mg/disc) and C2 (4.167 mg/disc) showed no statistical difference in antibacterial activity (zone of inhibition) and cumulative and conditioned release of therapeutic dose range for vancomycin in the results of the disk diffusion test and elution assay. The antibacterial inhibition zone from C1, C2 to C3 (8.33, 4.167 and 0.83 mg/disc, respectively) was measured from 2.54 to 2.13 cm but significantly declined at C4 and C5 (0.083 and 0.0083 mg/disc) from 1.67 to 1.23 cm in its diameter. This indicates preclinical cutoff value (over 4.167 mg/disc) of a dose concentration effective for the therapeutic purpose to maintain above the minimal inhibitory concentration. Comparably higher concentration of vancomycin-loading is more promising to maintain sustainable release in conditional setting of daily total PBS exchange over daily half exchanging. In cumulative measurement of HPLC assay, the vancomycin concentration was maintained sufficiently high enough to therapeutic range for two consecutive weeks. This natural polymer can maintain its continuous antibacterial activity until it is degraded over time for several weeks. However, it can be influenced by structural limitations of fibrin glue or a saturated state of affinity to vancomycin \[[@b2-jkns-2019-0161]\].

An animal study by Kroez et al. \[[@b19-jkns-2019-0161]\] indicated that the antibody titer for fibrin and thrombin peaked at 2 weeks and then gradually decreased in rabbit liver. This was in agreement with the present study results. Fibrin sealant was degraded and replaced by granulation tissue within 9 weeks \[[@b19-jkns-2019-0161]\]. To achieve complete eradication of infection, sustainable release of antibiotics to the dead space of the surgical wound is essential. Additionally, the antibiotic concentration should be maintained above the MIC for as long as possible to control infection efficiently. Our study revealed that even total exchange of PBS showed maintenance of vancomycin concentration over the MIC for at least four days. This suggests that if the body fluid is refreshed entirely (e.g., JP drainage or significant bleeding at the operation site), the fibrin glue can still release vancomycin for at least 4 days above the therapeutic dose. This indicates that the fibrin sealant can endure rapid turnover of body fluid. Total exchange and half exchange of PBS were performed assuming that surgical dead space usually changes its fluid component as serous fluid from surrounding tissue or vessels accumulates while postoperative drainage (e.g., baro-vac) removes fluid from the dead space. Our results emphasize that fibrin glue may maintain high concentrations of vancomycin in the surgical dead space in vivo even under total or half fluid exchange conditions. Moreover, if used in the dead space of surgical wounds, fibrin glue can also provide hemostasis and dead space filling along with antibiotic release.

As shown in this study, fibrin sealant can effectively release vancomycin *in vitro* environment at least 4 or 5 days at daily total and half exchange of PBS. These results can be affected by turnover rate of surgical space fluid. In our cumulative release measurement, fibrin sealant as a drug delivery vehicle can provide sustainable vancomycin release as high as 400 μg/mL at a maximum dose in 48 hours and maintained 2 weeks. Cumulative release of vancomycin will last more than 2 weeks and will maintain a sufficient therapeutic antibiotic level over MIC. However, conditional antibiotic release from fibrin sealant is diluted and reduced gradually for several days depending on PBS exchange rate mimicking the physiologic conditions such as drainage of postoperative bleeding or f luid through the surgical hemo-vac. This result implies that if the fluid turnover is slower than our conditional antibiotic elution tests, antibiotic embedded fibrin sealant can release antibiotics over therapeutic drug concentration as long as 2 weeks or more depending on the PBS exchange rate, which mimics physiological conditions such as postoperative bleeding or body fluid release. In this study, conditional elution test assumed that active bleeding or body fluid drainage occurred in surgical wound. Even under extreme in vitro conditions such as total exchange of PBS, effective concentration of vancomycin release over TDM remained for consecutive 4 days. As the body fluid drainage and its duration in vivo environment, the cumulative release of vancomycin can maintain a sufficiently higher level of therapeutic concentration than MIC for more than 2 weeks.

This Study was limited to 2 weeks of experiment and did not assume to obtain the result of the overall continuous antibiotic release during the period of fibrin glue degradation. Further investigation is needed to determine the trend of antibiotic release over a few weeks. Additionally, future studies should examine a variety of vancomycin concentrations to obtain the best concentration with fibrin sealant for outstanding clinical results. Moreover, this study focused only on vancomycin and not on other antibiotics. Other antibiotics with different chemical properties might show different pharmacokinetics or sustainability when combined with fibrin sealant as indicated by a previous study with PMMA \[[@b20-jkns-2019-0161]\]. The relationship between time and concentration differs among antibiotics because of their hydrophobic/hydrophilic status or molecular weight \[[@b2-jkns-2019-0161]\]. Thus, further studies should include other widely used antibiotics such as gentamycin or cephalosporin. The last limitation is that the *in-vitro* model cannot exactly match and explain the reality of *in-vivo* situations. In addition, the drug-impregnated fibrin sealant is usually not sufficient to cover the dead space of a wide surgical wound. However, this study emphasizes the use of fibrin sealant as an effective drug delivery vehicle for topical application in neurosurgical procedures to prevent or control focal infection site when combined with antibiotics.

CONCLUSION
==========

This *in vitro* study demonstrated the biodegradable fibrin sealant as a vehicle for sustainable antibiotic release in the test period. When simulating the *in-vitro* model of half and total fluid accumulation and resorption, fibrin glue could release vancomycin over the MIC for at least 4 or 5 days. This result emphasizes that fibrin glue is an effective drug delivery agent in addition to its benefits regarding hemostasis, sealing defects, and adhesive function, which have been well documented in many previous studies. Based on these experimental data, further investigations are required *in vivo* and in pilot clinical application to establish the optimal concentration of antibiotic load in the fibrin sealant. Further studies should also include a variety of medications such as gram-negative bacteria-covering antibiotics, antitumor agents, proteins, or antigens. Then, the fibrin sealant could be used as a drug delivery vehicle for neurosurgery as well as in other surgical fields.
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![Comparison of disk diffusion test inoculated with *Staphylococcus aureus* (MRSA, ATCC29213) on Blood Agar Plates for (A) control (fibrin sealant without vancomycin) on the left and (B) concentration 1 (C1, fibrin sealant with vancomycin) on the right. The diameter of the clear zone was measured after 24 hours (arrow).](jkns-2019-0161f1){#f1-jkns-2019-0161}

![HPLC measurement for ① cumulative vancomycin release for 2 consecutive weeks and ② two different Conditional vancomycin release each of daily total and half PBS exchange from day 1 to day 2 and sample collection for analysis. HPLC : high-performance liquid chromatography, PBS : phosphate buffer solution.](jkns-2019-0161f2){#f2-jkns-2019-0161}

![Relationship between peak area and concentration of vancomycin release measured and the process of calibrating concertation of vancomycin release in each PBS sampling for HPLC analysis. RSD : relative standard deviation, PBS : phosphate buffer solution, HPLC : high-performance liquid chromatography.](jkns-2019-0161f3){#f3-jkns-2019-0161}

![Comparison in zone of inhibition test for five different concentrations with respective standard deviation. \**p*\<0.05 in one way ANOVA, post-hoc analysis by Tukey's HSD showed *p*\<0.05 except for C1--C2 and C4--C5. ANOVA : analysis of variance.](jkns-2019-0161f4){#f4-jkns-2019-0161}

![Continuous release test - average vancomycin concentration with standard deviation (μg/mL) from vancomycin loaded fibrin sealant for C1 and C2 over 2 weeks of study periods.](jkns-2019-0161f5){#f5-jkns-2019-0161}

![Average vancomycin release (μg/mL) from vancomycin loaded fibrin sealant in C1 and C2 with total solution exchange every 24 hours for 5 days (e.g., rapid drainage by JP drain or significant bleeding in operation field).](jkns-2019-0161f6){#f6-jkns-2019-0161}

![Average vancomycin release (μg/mL) from vancomycin loaded fibrin sealant in C1 and C2 with half solution exchange every 24 hours for 5 days (e.g., natural drainage by JP drain or slowly body fluid exchange).](jkns-2019-0161f7){#f7-jkns-2019-0161}

###### 

Measurement in diameter (cm) of zone of inhibition in disk diffusion test

  Set    Types of disc concentration                               
  ------ ----------------------------- ------------- ------ ------ ------
  1      2.3/2.6/2.5                   2.3/2.8/2.4   2.1    1.7    1.4
  2      2.2/2.6/2.9                   2.4/2.8/2.6   2.3    1.6    1.2
  3      2.7/2.4/2.7                   2.8/2.7/2.7   2.0    1.7    1.1
  Mean   2.54                          2.61          2.13   1.67   1.23
  SD     0.07                          0.12          0.15   0.06   0.15

SD : standard deviation
